case 6 - introduction to type 2 diabetes Flashcards

1
Q

what is diabetes mellitus

A

metabolic diseases characterised by hyperglycaemia resulting from defects in insulin secretion, insulin action or both

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is type 2 diabetes

A

metabolic disorder caused by insulin resistance and insulin deficiency resulting in hyperglycaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is pre diabetes and how is it diagnosed

A

at high risk of developing type 2 diabetes:
Impaired glucose tolerance - IGT
Above normal glucose blood concentration after fasting (impaired glucose fasting - IFG)
Above normal HbA1c - 42-48 = pre diabetes and 48+ is diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is the epidemiology of type 2 diabetes

A

in 2015 there were over 415 million people with diabetes worldwide
Type 2 diabetes accounts for around 90% of cases

in the UK, around 3.9 million are diagnosed with diabetes in 2019
Steady increases in diabetes incidence and prevalence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

who is type 2 diabetes the most common in

A

more common in men than in women
65+ age group most affected
Increasing numbers diagnosed under 40 years of age
Childhood type 2 diabetes incidence also increasing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what ethnicity is diabetes the most common in

A

3-5 times increased prevalence in ethnic minority groups vs white communities.

south asians

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

in spite of lower BMI, what do south asians have:

A

more abdominal fat
More insulin resistance + hyperinsulinaemia
Increased inflammatory reponse
Lower adiponectin
More dyslipidaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what is the morbidity and mortality causes in type 2 diabetes

A

cardiovascular disease is the cause of death in around 70%
Commonest cause of chronic kidney disease
Commonest cause of lower limb amputation
Commonest cause of blindness in working population
Non-alcoholic fatty liver disease and most common liver disease in the world
10% of the NHS budget

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is the pathophysiology of type 2 diabetes

A
  • there are genetic predisposition and environmental risk factors
  • these risk factors lead to obesity, which leads to insulin resistance
  • this leads to decreased glucose uptake which then leads to hyperglycaemia
  • then hyperglycaemia leads to type 2 diabetes
  • also increased hepatic glucose output, caused by deranged insulin release can also lead to hyperglycaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are the non modifiable risk factors of type 2 diabetes

A

age
Ethnicity
Family history
Low birth weight
History of GDM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what are the modifiable risk factors for type 2 diabetes

A

obesity -approximately 80% of the risk for developing T2DM
Hypertension - 20mmhg increase was associated with 58% increase risk of diabetes
Dyslipidemia - low HDL, high triglycerides
PCOS - elevated androgens and insulin resistance
Poor dietary habit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is the linear relationship between obesity and type 2 diabetes

A

Visceral and abdominal fat have a much greater associated with type 2 diabetes than cutaneous fat
Variation in distribution of fat with age, ethnicity, and sex
Increased fat mass —> insulin resistance and type 2 diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what are the genetics linked to diabetes

A

polygenic
The risk of developing the condition is as high as 70% if both parents have suffered from the condition
First degree relatives of individuals with type 2 diabetes are about 3 times more likely to develop the disease
Monozygotic twins, there is a 50-90% concordance for developing the condition
Environments —> genetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are the steps in the key pathophysiological processes

A
  1. insulin resistance
  2. insulin secretory defect
  3. increased production of glucose by the liver
  4. loss of incretin effect
  5. other mechanisms such as insulin feedback and CNS changes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what processes does insulin lead to

A

Insulin leads to a number of anabolic processes, such as building larger molecules from smaller molecules, which are crucial to cellular survival, the growth of cells and tissues and maintaining normal homeostasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is the insulin receptor

A

a modified tyrosine kinase receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

describe the binding of this receptor and what happens

A

he insulin receptor is a modified tyrosine kinase receptor

when insulin, as the ligand, binds to the insulin receptor, you get the insulin signalling cascade

An important part of the insulin signalling cascade is the exocytosis of GLUT4 channels to the cell membrane and then the facilitated diffusion of glucose, which is in the blood of course, into the cell

Glucose is then used in glycolysis in cellular respiration so that we get energy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

in insulin resistance, what else does this increased glucose lead to

A

hyperglycaemia
Increased lipolysis
Increased proteolysis
Increased hepatic gluconeogenesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

what else is this glucose used for in anabolic processes and cellular growth

A

cellular respiration
Proteins and lipid synthesis
Inhibit hepatic gluconeogenesis
Promote hepatic glycogen synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what are the damaging molecules in obese people

A

free fatty acids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what are free fatty acids used as

A

used as a substrate, as an energy by the liver and gluconeogenesis is increased

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what is there less of because of this free fatty acid accumulation around the liver

A

there is less insulin feedback

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

what is there more of because of these free fatty acids

A

there is more gluconeogenesis and more blood glucose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

what happens in the muscles

A

the muscles will used more fatty acids instead of glucose, so there is less glucose taken up from the blood and therefore less glycogenesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

what is the relationship between free fatty acids and the beta cell

A

FFAs are toxic to the beta cell and therefore less insulin is released again leading to problems with hypoglycaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

what mediators are increased with increased lipolysis

A

inflammatory mediators;
released by adipocytes:
- TNF alpha and IL-6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

what kind of activity is increased with lipolysis

A

greater sympathetic activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

what happens to the beta cells as hyperglycaemia develops

A

beta cells secrete more insulin to deal with increase in glucose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

what happens when the beta cell mass is depleted

A

insulin levels fall and there is secretory failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

what is shown during autopsy of patients with T2DM

A

increased deposition of amyloid within islet cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

what is toxic to beta cells

A

hyperglycaemia (glucotoxicity)
high lipids (lipotoxicity)

32
Q

what are beta cells damaged by

A

amyloid deposits
Inflammation
Glucotoxicity
Lipotoxicity

33
Q

describe the mechanism of action of increased hepatic gluconeogenesis

A
  1. Increased availability of gluconeogenic substrates e.g fatty acids leads to increased gluconeogenesis
  2. Resistance of the liver to the action of insulin leads to improper suppression of hepatic gluconeogenesis
  3. Elevated glucagon due to resistance to feed back suppression from insulin and glucose
34
Q

what are incretins

A

gut peptide hormones that are secreted after nutrient intake and whose primary role is to stimulate insulin release

35
Q

what is GLP1 secreted by

A

GLP-1L cells located in the ileum and large intestine

36
Q

what is GIP secreted by

A

GIP K cells located in the proximal duodenum

37
Q

what are the symptoms and signs of type 2 diabetes

A

asymptomatic
Polyuria and nocturia
Lethargy
Weight change (weight loss once severe insulin deficiency occurs)
Thrush/genetial itching
Prolonged healing time
Visual disturbance

38
Q

how is type two diabetes diagnosed

A

diabetes symptoms (e/g polyuria, polydipsia) plus:
HbA1c of >48mmol/mol or
A random venous plasma glucose concentration of more than 11.1mmol/L or
A fasting plasma glucose concentration of more than 7 mmol/L or
Two hour plasma glucose concentrations more than 11.1 mmol/L two hours after 75g anhydrous glucose in an oral glucose tolerance test (OGTT)

39
Q

how is diabetes type 2 diagnosed without symptoms

A

two separate positive results from separate days

40
Q

when do you not use Hb1Ac as diagnoses technique

A

rapid onset of diabetes - an increase in HbA1c may not be detected until a few weeks later
Pregnancy - HbA1c typically lower
Conditions with decreased red cell survival, haemolytic anaemia, severe blood loss, splenomegaly, antiretroviral drugs
Increased red cell survival may increase Hb1Ac e.g splenectomy
Renal dialysis reduced Hb1Ac especially if treated with erythropoietin
Iron and B12 deficiency and their treatment

41
Q

for the above (excluding pregnancy) how do we diagnose diabetes then

A

For the above (except pregnancy) diagnose by fasting glucose more than 7mmol/L twice, or once with symptoms

42
Q

what are the aims of treatment

A
  1. remission
  2. improve glycemic control
  3. treat co-existing cardiovascular risk factors
43
Q

what are the management factors of type 2 diabetes

A

lifestyle modification - NHS diabetes prevention programme (DPP)
ASSESS cardiovascular risk - e.g QRISK3
Diet and exercise
Weight loss - aim 10% reduction
Can be enough to put diabetes 2 into remission
smoking cessation

44
Q

what are the treatment targets for type 2 diabetes

A

-HbA1c <48mmol/mol if not on medication which cause hypoglycaemia ( otherwise <53mmol/mol)
-BP <140/80 (<130/80 if complications present)
-Total cholesterol <4.0 mmol/l, LDL<2.0 mmol/l, HDL >1 (men) >1.2 (women)

45
Q

when is there treatment escalation

A

if Hb1Ac is greater than 58mmol/L

46
Q

what is screened for annually in people with type 2 diabetes

A

retinopathy - retinal photography
Nephropthaty - urine dipstick, albumin creatine ratio, urea and electrolytes
Neuropathy - foot inspection , 10g monofilament or 128Hz turning fork tests and pulses

47
Q

what are the different pharmacological treatments in type 2 diabetes

A

metformin
SGLT2 inhibitors
Sulphonylurea
DPP4 inhibitors
Thiazoidendiones
GLP-1 analogues
Insulin
Meglitindes
Alpha glucosidase inhibitors

48
Q

what is metformin and what does it do

A

it reduces insulin resistance and hepatic glucose output

it reduces weight and suppresses appetite

49
Q

what are the side effects of metformin

A

Side effects; diarrhoea, nausea, anorexia, lactic acidosis

50
Q

what are the SGLT2 inhibitors MoA

A

reduce glucose reabsorption from proximal tubule of nephron

51
Q

what are the additional effects of SGLT2 inhibitors

A

Additional effects; weight loss, blood pressure lowering, CVD protection, renal protection

52
Q

what are the dosage values of metformin

A

Dosage:: Dapagliflozin 10mg OD, Canagliflozin 100mg – 300mg, Empagliflozin 10-25mg

53
Q

what are the side effects of SGLT2 inhibitors

A

increased risk of urinary tract infection, DKA

54
Q

what does sulphonylurea do

A

increases insulin secretion

bind to sulphonyurea receptor 9SUR-1) leading to closure of ATP K+ channel

55
Q

what is the dosage of sulphonylurea

A

Dosage: *gliclazide 40mg OD, increased to 320mg in divided doses if needed

56
Q

what are the side effects of sulphonylurea

A

hypoglycaemia, weight gain

57
Q

what are DPP4 inhibitors

A

dipeptidyl peptidase 4 inhibitors

prevent breakdown of incretins, preserving incretin effect

58
Q

what is the combination therapy DPP4 inhibitors are used in

A

Usually combination therapy with metformin/metformin + sulphonylurea

59
Q

what is the dosage of DPP4 inhibitors

A

Dosage: alogliptin 25mg OD, saxagliptin 5mg OD

60
Q

what are the side effects of DPP4 inhibitors

A

GI disturbance, rash, headache, sore throat

61
Q

what are thiazolidinediones

A

peroxisome proliferator activted receptor gamma agonist

62
Q

PPAR gamma - features

A

is a nuclear receptor
activation decreases insulin resistance

63
Q

what is the dosage of PPAR gamma

A

*Dosage: pioglitazone 15mg OD, increased to 45mg OD if required

64
Q

what are the side effects

A

Side effects; increased fracture risk, fluid retention, heart failure, small increased risk of bladder cancer

65
Q

what are the effects of GLP-1 in the pancreas

A

increased insulin synthesis and secretion
Decreased glucagon secretion
Increased beta cell survival

66
Q

what are the effects of GLP-1 in the CNS

A

decreased food intake
increased saiety

67
Q

what are the effects of GLP-1 in the stomach and intestine

A

decreased gastric emptying
decreased bowel motility
decreased acid secreiton

68
Q

what are the effects of GLP-1 in the liver/fat/muscle

A

increased glucose uptake
Increased glycogen synthesis
Increased lipogenesis in fat

69
Q

when does one give GLP-1 analogues

A

BMI of 35kg/m2 or higher and medical problems associated with obesity

OR

BMI less than 35kg/m2 and insulin therapy would have significant implications, or weight loss would benefit other significant obesity-related comorbidities

70
Q

what are examples of GLP-1 analogues

A

*Examples: Liraglutide 0.6mg-1.8mg OD, Semaglutide 1mg once weekly subcutaneous injections

71
Q

what are side effects of GLP-1 analogues

A

Side effects - vomiting, nausea, diarrhoea, pancreatitis (rare)

72
Q

when should insulin therapy be considered

A

inadequate control deste dual therapy (metformin plus another oral anti diabetic drug)

Oral anti diabetic drugs are contraindicated or not tolerated

73
Q

what would the reasons be for not initiating therapy

A

obesity
physical and mental health - hypoglycaemia
anxiety about needles
personal preference
concerns relating to license to drive group 2 vehicles

74
Q

what is the most common insulin therapy

A

*Neutral Protamine Hagedorn (NPH)insulin (injectedonce or twice daily according to need)

*NPH plus a short acting insulin should be consideredif HbA1c is 75 mmol/mol higher
OR
*Longer acting insulin analogues e.g. insulin detemir or insulin glargine

75
Q

what is hypoglycaemia

A

any blood glucose less than 4.0mmol/L

76
Q

what are the symptoms of hypoglycaemia

A

hunger, paliptations, sweating, tremors

77
Q

what can people with hypoglycaemia not do

A

drive a group 2 vehicle - bus or lorry